Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Trial of Bevacizumab Plus Cisplatin/Pemetrexed in Chemotherapy-Naive, Inoperable Malignant Pleural Mesothelioma
jRCT2080223239Phase 2Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jun 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in pleural mesothelioma, sponsored by Chugai Pharmaceutical Co., Ltd. Started Jun 2016; status: completed.
02
Drugs
bevacizumab
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on jRCT2080223239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223239.